Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 98

Sort by

Sort Order Select

Journal Articles

Indolent Lymphoma: Well Tolerated, Fixed Duration Treatment Involving Bendamustine, Rituximab and Acalabrutinib for Front-Line Waldenström's Macroglobulinaemia That Induce Deep Clinical Responses

Adam Suleman, Kim Roos, Kathryn Mangoff, Yidi Jiang, Gail Klein, Rebecca McClure, Nicholas Allen Forward, Mona Shafey, Anna Nikonova, Michael Sebag, David MacDonald, Diego Villa, Irwindeep Sandhu, Mohammed Aljama, Jean-Francois Larouche, Heidi Simmons, Monica Gallucci, George A. Tomlinson, Neil Berinstein

Blood (2024) 144 (Supplement 1): 6291.

https://doi.org/10.1182/blood-2024-203317

Published: 2024

Journal Articles

Omission of Bleomycin in Limited Stage Classic Hodgkin Lymphoma Patients with a Negative PET Scan Following 2 Cycles of ABVD Is Associated with Comparable Outcomes and Reduced Pulmonary Toxicity

Jiayu Yang, Diego Villa, Alina S. Gerrie, Petter Tonseth, Don C. Wilson, Francois Benard, Graham W. Slack, Christopher P. Venner, Andrea C. Lo, David W. Scott, Laurie H. Sehn, Kerry J. Savage

Blood (2024) 144 (Supplement 1): 461.

https://doi.org/10.1182/blood-2024-194858

Published: 2024

Journal Articles

Utility of the Central Nervous System International Prognostic Index (CNS-IPI) in Patients with Primary Mediastinal B-Cell Lymphoma Treated with Rituximab-Containing Chemoimmunotherapy

Jiayu Yang, Anna R. Hayden, Diego Villa, Aixiang Jiang, Alina S. Gerrie, Christopher P. Venner, Pedro Farinha, David W. Scott, Laurie H. Sehn, Kerry J. Savage

Blood (2024) 144 (Supplement 1): 574.

https://doi.org/10.1182/blood-2024-198794

Published: 2024

Journal Articles

Clinical Characteristics and Outcomes of Aggressive Transformation in Splenic Marginal Zone Lymphoma: An International Study of 111 Patients

Blood (2024) 144 (Supplement 1): 3019.

https://doi.org/10.1182/blood-2024-204328

Published: 2024

Journal Articles

Richter Transformation (RT) in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Comparison of Two Eras

Jean-Nicolas Champagne, Steven Huang, Rayan Ramadan, Christopher P. Venner, Khaled Ramadan, Laurie H. Sehn, Kerry J. Savage, Diego Villa, David W. Scott, Waleed Alduaij, Cynthia L. Toze, Alina S. Gerrie

Blood (2024) 144 (Supplement 1): 5095.

https://doi.org/10.1182/blood-2024-198028

Published: 2024

Journal Articles

Retreatment with R-CHOP-like Therapy in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma (DLBCL)

Jean-Nicolas Champagne, Diego Villa, Alina S. Gerrie, Christopher P. Venner, Graham W. Slack, Pedro Farinha, Jeffrey W Craig, Laura Hilton, Kerry J. Savage, David W. Scott, Laurie H. Sehn

Blood (2024) 144 (Supplement 1): 109.

https://doi.org/10.1182/blood-2024-201819

Published: 2024

Journal Articles

Phase III Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Eculizumab

Phillip Scheinberg, Diego Villa Cle, Berangere Devalet, Valentina Giai, Cristina Barrenetxea Lekue, Hsuan-Yu Lin, Zsolt Nagy, Jun-ichi Nishimura, Jens Panse, Agnieszka Piekarska, Jörg Schubert, Kazutaka Sunami, Mustafa Yenerel, Anita Appius, Brittany Gentile, Shino Iwase, Himika Patel, Sasha Sreckovic, Austin G. Kulasekararaj

Blood (2024) 144 (Supplement 1): 1313.

https://doi.org/10.1182/blood-2024-200745

Published: 2024

Journal Articles

Zilovertamab Vedotin in Combination with Nemtabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort C of the Open-Label, Phase 2 Waveline-006 Study

Ewa Paszkiewicz-Kozik, Claudia Moreira, Mehmet Turgut, Marcelo Garrido, Ingrid Glimelius, Seung Tae Lee, Yazeed Sawalha, Yixin Ren, Katherine Ryland, Uzor C. Ogbu, Diego Villa

Blood (2024) 144 (Supplement 1): 3025.

https://doi.org/10.1182/blood-2024-205985

Published: 2024

Journal Articles

CNS Relapse in High-Grade B-cell Lymphoma with MYC and BCL2 Rearrangements and Dark-Zone Signature-Expressing DLBCL

Waleed Alduaij, Aixiang Jiang, Diego Villa, Brett J Collinge, Susana Ben-Neriah, Merrill Boyle, Barbara Meissner, Laura K Hilton, Pedro Farinha, Graham W. Slack, Jeffrey W Craig, Alina S. Gerrie, Ciara L Freeman, Andrew J Mungall, Christian Steidl, Laurie H. Sehn, David W. Scott, Kerry J. Savage

Blood blood.2024025725.

https://doi.org/10.1182/blood.2024025725

Published: 2024

Includes: Supplemental data

Journal Articles

Unbalanced MYC break-apart FISH patterns indicate the presence of a MYC rearrangement in HGBCL-DH- BCL2

Brett Collinge, Susana Ben-Neriah, Laura K. Hilton, Waleed Alduaij, Tracy Tucker, Graham W. Slack, Pedro Farinha, Jeffrey W. Craig, Merrill Boyle, Barbara Meissner, Diego Villa, Alina S. Gerrie, Laurie H. Sehn, Kerry J. Savage, Ryan D. Morin, Andrew J. Mungall, Christian Steidl, David W. Scott

Blood (2024) 144 (15): 1611–1616.

https://doi.org/10.1182/blood.2024025603

Published: 2024

Includes: Supplemental data

Journal Articles

Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy

Yucai Wang, Melissa C. Larson, Steven R. Hwang, Anita Kumar, Ashlee Joseph, Brian T. Hill, Taylor R. Brooks, David A. Bond, Kami J. Maddocks, Alexey Danilov, Christine McCarthy, Jia Ruan, Imran A. Nizamuddin, Brad S. Kahl, Natalie S. Grover, Nazneen B. Khan, Evguenia Ouchveridze, Aung M. Tun, Philip Young, Craig A. Portell, Zoey I. Harris, Javier L. Munoz, Patrick M. Reagan, Georgio Pongas, Izidore S. Lossos, Christine E. Ryan, Reid W. Merryman, Firas Baidoun, Muhamad Alhaj Moustafa, Drew Gerber, Sabarish R. Ayyappan, Brian K. Link, Arash Velayati, Irl Brian Greenwell, Lauren G Banaszak, Priyanka A Pophali, Anthony C. Stack, Marcus R. Messmer, Mayur Narkhede, Amitkumar N. Mehta, Preetesh Jain, Michael L. Wang, Tamara K. Moyo, Nilanjan Ghosh, Rahul S. Bhansali, Stefan K. Barta, Manali K. Kamdar, Jacob Anna, Alexander V. Stanisic, Reem Karmali, Laveniya Kugathasan, Diego Villa, Matthew J. Maurer, James R. Cerhan, Jonathon B. Cohen, Peter Martin

Blood (2023) 142 (Supplement 1): 300.

https://doi.org/10.1182/blood-2023-182942

Published: 2023

Journal Articles

Favorable Outcomes of Splenic Marginal Zone Lymphoma in an International Study of 934 Patients with Long Follow-up

Blood (2023) 142 (Supplement 1): 4396.

https://doi.org/10.1182/blood-2023-173247

Published: 2023

Journal Articles

Rituximab Combined with Chemotherapy and Acalabrutinib Prior to Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: The Rectangle Trial

Diego Villa, Jean-Francois Larouche, Matthew C. Cheung, Mary-Margaret Keating, Katherine Zukotynski, Petter Tonseth, Samantha Mayo, Robert Laister, David W. Scott, John Kuruvilla

Blood (2023) 142 (Supplement 1): 3042.

https://doi.org/10.1182/blood-2023-179375

Published: 2023

Journal Articles

An International Multicohort Study of Conditional Survival and Cause of Death after Achieving Event-Free Survival at 24 Months in Patients with Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1656.

https://doi.org/10.1182/blood-2023-182747

Published: 2023

Journal Articles

Indolent Lymphoma: High CR and VGPR Rate with Fixed Duration Bendamustine, Rituximab and Acalabrutinib in Waldenstroms Macroglobulinaemia (BRAWM)

Neil Berinstein, Kim Roos, Kathryn Mangoff, Yidi Jiang, Gail Klein, Rebecca McClure, Nicholas Forward, Mona Shafey, Anna Nikonova, David MacDonald, Diego Villa, Irwindeep Sandhu, Mohammed Aljama, Jean-Francois Larouche, Monica Gallucci, Heidi Simmons

Blood (2023) 142 (Supplement 1): 3037.

https://doi.org/10.1182/blood-2023-186347

Published: 2023

Journal Articles

Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population

Blood (2023) 141 (20): 2493–2507.

https://doi.org/10.1182/blood.2022018248

Published: 2023

Includes: Supplemental data

Journal Articles

FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma

Blood (2022) 140 (Supplement 1): 2292–2295.

https://doi.org/10.1182/blood-2022-157194

Published: 2022

Journal Articles

Long-Term Outcomes of Patients Aged 65 Years or Older with Peripheral T-Cell Lymphoma, Not Otherwise Specified (PTCL-NOS) and T-Follicular Helper T-Cell Lymphoma (TFHTCL) Treated with Curative Intent CHOP(like) Chemotherapy

Henry S. Ngu, Diego Villa, Alina S. Gerrie, Christopher P. Venner, Andrew Lytle, Brian Skinnider, Jeffrey W. Craig, Graham W. Slack, David W. Scott, Laurie H. Sehn, Kerry J. Savage

Blood (2022) 140 (Supplement 1): 3713–3715.

https://doi.org/10.1182/blood-2022-168586

Published: 2022

Journal Articles

Risk of Central Nervous System Involvement in High-Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements: Analysis of a Population-Based Cohort with Routine Fluorescence in Situ Hybridization Testing in British Columbia

Waleed Alduaij, Aixiang Jiang, Diego Villa, Brett Collinge, Susana Ben-Neriah, Merrill Boyle, Barbara Meissner, Laura K Hilton, Pedro Farinha, Graham W Slack, Jeffrey W. Craig, Alina S. Gerrie, Ciara L. Freeman, Andrew J. Mungall, Christian Steidl, Laurie H. Sehn, David W. Scott, Kerry J. Savage

Blood (2022) 140 (Supplement 1): 1332–1333.

https://doi.org/10.1182/blood-2022-159356

Published: 2022

Journal Articles

Next Generation BTK Inhibitor Acalabrutinib with Bendamustine-Rituximab in First Line Waldenstrom's Macroglobulinemia: The Brawm Study

Neil L Berinstein, Gail Klein, Katerina Welsh, Rebecca McClure, Nicholas Allen Forward, Mona Shafey, Anna Nikonova, David MacDonald, Diego Villa, Irwindeep Sandhu, Mohammed A Aljama, Jean-François Larouche

Blood (2022) 140 (Supplement 1): 9383–9384.

https://doi.org/10.1182/blood-2022-169245

Published: 2022

NARROW

Indolent Lymphoma: Well Tolerated, Fixed Duration Treatment Involving Bendamustine, Rituximab and Acalabrutinib for Front-Line Waldenström's Macroglobulinaemia That Induce Deep Clinical Responses

Omission of Bleomycin in Limited Stage Classic Hodgkin Lymphoma Patients with a Negative PET Scan Following 2 Cycles of ABVD Is Associated with Comparable Outcomes and Reduced Pulmonary Toxicity

Utility of the Central Nervous System International Prognostic Index (CNS-IPI) in Patients with Primary Mediastinal B-Cell Lymphoma Treated with Rituximab-Containing Chemoimmunotherapy

Clinical Characteristics and Outcomes of Aggressive Transformation in Splenic Marginal Zone Lymphoma: An International Study of 111 Patients

Richter Transformation (RT) in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Comparison of Two Eras

Retreatment with R-CHOP-like Therapy in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma (DLBCL)

Phase III Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Eculizumab

Zilovertamab Vedotin in Combination with Nemtabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort C of the Open-Label, Phase 2 Waveline-006 Study

CNS Relapse in High-Grade B-cell Lymphoma with MYC and BCL2 Rearrangements and Dark-Zone Signature-Expressing DLBCL

Unbalanced MYC break-apart FISH patterns indicate the presence of a MYC rearrangement in HGBCL-DH- BCL2

Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy

Favorable Outcomes of Splenic Marginal Zone Lymphoma in an International Study of 934 Patients with Long Follow-up

Rituximab Combined with Chemotherapy and Acalabrutinib Prior to Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: The Rectangle Trial

An International Multicohort Study of Conditional Survival and Cause of Death after Achieving Event-Free Survival at 24 Months in Patients with Mantle Cell Lymphoma

Indolent Lymphoma: High CR and VGPR Rate with Fixed Duration Bendamustine, Rituximab and Acalabrutinib in Waldenstroms Macroglobulinaemia (BRAWM)

Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population

FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma

Long-Term Outcomes of Patients Aged 65 Years or Older with Peripheral T-Cell Lymphoma, Not Otherwise Specified (PTCL-NOS) and T-Follicular Helper T-Cell Lymphoma (TFHTCL) Treated with Curative Intent CHOP(like) Chemotherapy

Risk of Central Nervous System Involvement in High-Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements: Analysis of a Population-Based Cohort with Routine Fluorescence in Situ Hybridization Testing in British Columbia

Next Generation BTK Inhibitor Acalabrutinib with Bendamustine-Rituximab in First Line Waldenstrom's Macroglobulinemia: The Brawm Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only